Novartis AG - Return On Total Capital
Novartis AG's Fiscal Year is From January To December - All Figures are in Percent.
The item "Return-On-Total-Capital" stands at 19.26 percent as of 09/30/2025.
As of the end of Novartis AG's third quarter, the item "Return On Total Capital" stands at 19.26 Percent. This represents an increase of 0.57 percentage points compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -4.56 percentage points compared to the value the year prior.
The 1 year change in percentage points is -4.56.
The 3 year change in percentage points is -5.55.
The Serie's change in percentage points from it's minimum value, on 12/31/2022, to it's latest available value, on 09/30/2025, is +11.15.
The Serie's change in percentage points from it's maximum value, on 03/31/2022, to it's latest available value, on 09/30/2025, is -7.22.
Return On Total Capital for Related Companies:
| Logo | Name | Market Cap (USD) |
|---|---|---|
 | Eli Lilly and Company - Return On Total Capital | 905,699,262,464.00 |
 | Johnson & Johnson - Return On Total Capital | 486,508,953,600.00 |
 | AbbVie Inc - Return On Total Capital | 399,570,305,024.00 |
 | Roche Holding AG - Return On Total Capital | 317,433,206,677.55 |
 | AstraZeneca PLC - Return On Total Capital | 280,205,508,085.11 |